Deniene King, NP
Adult Health · Ann Arbor, MINPI 1093107948
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.2% of the total across 348 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,007, 3.6 times the $1,397 reported in 2021. Among adult health clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $40.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$1K
- Lundbeck LLC$1K
- plus $3K from 12 others
What the payments were for
- Consulting fees$7405%
- Food & beverage$12,92991%
- Education$5114%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 34 | $2,368 |
| E.r. Squibb & Sons, L.L.C. | 47 | $2,223 |
| Otsuka America Pharmaceutical, Inc. | 51 | $2,080 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $1,776 |
| AbbVie | 47 | $1,260 |
| Lundbeck LLC | 41 | $1,074 |
| Neurocrine Biosciences, Inc. | 18 | $895 |
| Alkermes, Inc. | 12 | $583 |
| Axsome Therapeutics, Inc. | 11 | $391 |
| Corium, LLC | 10 | $342 |
| Sunovion Pharmaceuticals Inc. | 20 | $274 |
| Braeburn Inc. | 2 | $234 |
| Supernus Pharmaceuticals, Inc. | 3 | $195 |
| Johnson & Johnson | 3 | $143 |
| Biohaven Pharmaceuticals, Inc. | 1 | $123 |
| Cequr Corporation | 1 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $94 |
| OWP Pharmaceuticals, Inc. | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$1,188
- LYBALVI$993
- CAPLYTA$969
- VRAYLAR$618
- COBENFY$612
- INGREZZA$607
- ARISTADA$488
- UZEDY$469
- AUSTEDO$377
- Austedo XR$243
- AJOVY$232
- BRIXADI$143
- QELBREE$125
- Auvelity$125
- NURTEC ODT$123
- ARISTADA INITIO$122
- ABILIFY MAINTENA$121
- ABILIFY ASIMTUFII$121
- ADLARITY$115
How this compares
$14,180 in reported general payments places this provider in the 95th percentile of 527 adult health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 48 | $22,437 |
| VraylarCariprazine Hcl | 13 | $17,589 |
| TrintellixVortioxetine Hydrobromide | 19 | $13,515 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 41 | $3,129 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 25 | $2,415 |
| Trazodone Hcl | 43 | $2,003 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 89 | $1,590 |
| Dextroamphetamine Sulfate | 14 | $1,321 |
| Aripiprazole | 53 | $1,208 |
| Bupropion XlBupropion Hcl | 46 | $1,027 |
| Quetiapine Fumarate | 59 | $1,009 |
| Methylphenidate Hcl | 30 | $965 |
| Clonazepam | 115 | $947 |
| Doxepin Hcl | 29 | $873 |
| Lorazepam | 67 | $844 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,260 | $17,58913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $94 | $13,51519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 527 adult health providers in Michigan.
Other adult health in Ann Arbor
- Susanne QuallichAnn Arbor$42K
- Danmar DomingoAnn Arbor$5K
- Wei LuoAnn Arbor$4K
- Jacqueline BrewerSterling Heights$138K
- Linda Morris McCoyGrand Rapids$59K
- Sarita RaoCanton$51K
- Nancy BermanSouthfield$39K
- Michelle MillerQuincy$24K
- Adama JohnsonEastpointe$14K
- Bridget BonelloWyandotte$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.